Intra-hepatic Chemotherapy in Patient With Non-resectable Liver Metastases From Breast Cancer
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial evaluating intra-hepatic chemotherapy with oxaliplatin every second
week in combination with systemic capecitabine and in patients with a HER2-positive tumour in
combination with trastuzumab (Herceptin®) in patient with non-resectable liver metastases
from breast cancer.
Only patients without extrahepatic disease are included.